BackJade Biosciences Overview

Jade Biosciences Total Current Liabilities

Track Jade Biosciences's total current liabilities ($22M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$22.29M
822.30% YoYΔ $19.88M vs prior year quarter

Peer average

Loading

Jade Biosciences Total Current Liabilities History

Loading

Jade Biosciences vs. peers: Total Current Liabilities Comparison

Loading

Jade Biosciences Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Jade Biosciences (JBIO) FAQ

The latest total current liabilities for JBIO is $22M as of March 2026. That compares with $2.4M in the prior-year period — up 822.3% year over year. Investors often review this figure alongside Jade Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, JBIO's total current liabilities moved from $2.4M to $22M — a 822.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jade Biosciences's operating scale or balance-sheet position.

A total current liabilities figure of $22M for JBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting JBIO's total current liabilities ($22M), review year-over-year change from $2.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Jade Biosciences's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.